Skip to main content

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Clinical Trial Grant
Duke Scholars

Awarded By

Amgen, Inc.

Start Date

May 13, 2025

End Date

May 11, 2030
 

Awarded By

Amgen, Inc.

Start Date

May 13, 2025

End Date

May 11, 2030